FREE Account Opening + No Clearing Fees

Ganga Pharmaceuticals Ltd IPO (Ganga Pharmaceuticals IPO) Detail

January 29, 2016 - February 9, 2016

Ganga Pharmaceuticals IPO is a fixed price issue of Rs 1.54 crores.

Ganga Pharmaceuticals IPO bidding started from January 29, 2016 and ended on February 9, 2016. The shares got listed on BSE SME on February 22, 2016.

Ganga Pharmaceuticals IPO price is ₹15 per share. The minimum lot size for an application is 8000 Shares. The minimum amount of investment required by retail investors is ₹120,000.

First Overseas Capital Limited is the book running lead manager of the Ganga Pharmaceuticals IPO, while Kfin Technologies Limited is the registrar for the issue.

Refer to Ganga Pharmaceuticals IPO RHP for detailed information.

Ganga Pharmaceuticals IPO Details

IPO Date January 29, 2016 to February 9, 2016
Listing Date February 22, 2016
Face Value ₹10 per share
Price ₹15 per share
Lot Size 8000 Shares
Total Issue Size1,024,000 shares
(aggregating up to ₹1.54 Cr)
Issue Type Fixed Price Issue IPO
Listing At BSE SME
Share holding pre issue3,037,500
Share holding post issue40,615,000
Market Maker portion56,000 shares

Ganga Pharmaceuticals IPO Lot Size

Investors can bid for a minimum of 8000 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.

Application Lots Shares Amount
Retail (Min) 1 8000 ₹120,000
Retail (Max) 1 8000 ₹120,000
Lot Size Calculator

Ganga Pharmaceuticals IPO Promoter Holding

The promoters of the company are:

1. Mr. Bharat B. Sharma
2. Mrs. Srijana B. Sharma

Share Holding Pre Issue 91.05%
Share Holding Post Issue 68.09%

About Ganga Pharmaceuticals Ltd

Incorporated in 1994, Ganga Pharmaceuticals Ltd (GPL) is engaged in production of quality Bulk Ayurvedic Medicines in Mumbai. Apart from manufacturing, the company is also into marketing, distribution of Bulk Ayurvedic Medicines all over Maharashtra.

Company is manufacturing the following proprietary products:

1) Ampachan Vati;
2) Khadira Vati;
3) Nirmalaya churna

Company's products are available in liquid dosage form and solid dosage forms. Liquid dosage form includes Oil-based products and solid dosage forms includes Powder-based products, Tablets, and Pills.

Key Performance Indicator

Objects of the Issue (Ganga Pharmaceuticals IPO Objectives)

The object of the issue are to:

1. Enhance Company�s visibility, brand name for future growth opportunities;
2. Creating a public trading market for the Equity Shares of the Company by listing them on BSE;
3. General corporate expenses;
4. To meet the expenses of the Issue.

Ganga Pharmaceuticals IPO Review (Avoid)

[Dilip Davda]  

Issue is aggressively priced. Only risk savvy investors may consider investment for long term.

Read detail review...

Ganga Pharmaceuticals IPO Prospectus

Ganga Pharmaceuticals IPO Rating

Rating:Rated 3.5 stars
Vote Here ...

Ganga Pharmaceuticals IPO Listing Details

Listing Date February 22, 2016
BSE Script Code 539680
NSE Symbol
ISIN INE615T01017
Final Issue Price ₹15 per share

Pre-Open Session - BSE

Listing Day Trading Information

Price Details
Final Issue Price
Last Trade

Check IPO Performance…

Ganga Pharmaceuticals Ltd Contact Details

Ganga Pharmaceuticals Ltd
1 - A, 802, N.G. Suncity Ph II,
Kandivali East,
Mumbai 400101,Maharashtra
Phone: +91 250 609 8333/444

Ganga Pharmaceuticals IPO Registrar

Kfin Technologies Limited

Phone: 04067162222, 04079611000

Ganga Pharmaceuticals IPO - Buy or Not

Ganga Pharmaceuticals IPO Recommendation Summary

Review By Subscribe Neutral Avoid
Brokers 0 0 1
Members 0 0 0

Read All Reviews Post Your Review Manage Reviews

SME IPO Enquiry

SME Company Owners
We could help you get listed on the stock market.

Contact us Today

Check our SME IPO Guide New

Ganga Pharmaceuticals IPO FAQs

Ganga Pharmaceuticals IPO is a SME IPO of 1,024,000 equity shares of the face value of ₹10 aggregating up to ₹1.54 Crores. The issue is priced at ₹15 per share. The minimum order quantity is 8000 Shares.

The IPO opens on January 29, 2016, and closes on February 9, 2016.

Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE SME.

The Ganga Pharmaceuticals IPO opens on January 29, 2016 and closes on February 9, 2016.

Ganga Pharmaceuticals IPO lot size is 8000 Shares, and the minimum amount required is ₹120,000.

You can apply in Ganga Pharmaceuticals IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.

The finalization of Basis of Allotment for Ganga Pharmaceuticals IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Ganga Pharmaceuticals IPO allotment status.

The Ganga Pharmaceuticals IPO listing date is on February 22, 2016.
Open an Instant Account with Zerodha

Ganga Pharmaceuticals IPO Message Board

Ranked Members of Forum  Ranked Members | Members with Most Likes



7. dipak |   Link |  Bookmark |February 17, 2016 9:15:10 AM
Bjp govt is doing nothing apart from gv his long gyaaaaan and bhaiyo and beheno................complty disgusting gvt
6. Jugendra Singh |   Link |  Bookmark |February 17, 2016 6:22:44 AM
Very Bed
5. Vaibhav |   Link |  Bookmark |February 9, 2016 10:42:41 PM
Dilip ji please Update the New SME ipo :- YLPH EDUCATION SOLUTIONS LIMITED
5.1. Vaibhav |   Link |  Bookmark |February 9, 2016 10:43:53 PM
4. kiran |   Link |  Bookmark |January 29, 2016 2:52:07 PM
How to buy this, i dont this ipo see in HDFCSEC ipo list.
3. kiran |   Link |  Bookmark |January 29, 2016 2:51:16 PM
How to buy this, i dont see HDFCSEC ipo list.
2. Dilip Davda |   Link |  Bookmark |January 25, 2016 11:54:01 AM
Top Contributor Top Contributor (200+ Posts, 300+ Likes)
Ganga Pharma BSE SME IPO opening and closing dates deferred to 29.01.16 to 09.02.16. Please make a note of this

Dilip Davda

Dilip Davda
SEBI registered Research Analyst

Read my IPO Reviews

1. Septa |   Link |  Bookmark |January 23, 2016 6:49:55 PM (4000+ Posts, 4600+ Likes)
i just read the prospects they r asking 109 PE...... big avoid better SME pharma companies with PE 10 is available which i have in portfolio
1.1. arbandyo |   Link |  Bookmark |January 28, 2016 3:49:24 PM
septa sir do u see pharma sector is a good buy in this juncture more precisely in the global turmoil,if u could name some of SME pharma to bet on.